Cat. No.: HY-111502

Y06036

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with K_d value of 82 nM. Antitumor activity.

For research use only. We do not sell to patients.

Purity: 98.57%
CAS No.: 1832671-96-1
Formula: C₁₆H₁₅BrN₂O₅S
Molecular Weight:427.27

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Y06036 Chemical Structure

CAS No.: 1832671-96-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with K_d value of 82 nM^[1]. Antitumor activity^[1].

IC₅₀ & Target^[1]

BRD4(1)

82 nM (Kd)

All Epigenetic Reader Domain Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>5 μM Compound: 6i	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay	[PMID: 29566488]
CWR22R	IC₅₀	1.5 μM Compound: 6i	Antiproliferative activity against AR-positive human 22Rv1 cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay Antiproliferative activity against AR-positive human 22Rv1 cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay	[PMID: 29566488]
DU-145	IC₅₀	>6 μM Compound: 6i	Antiproliferative activity against AR-negative human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay Antiproliferative activity against AR-negative human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay	[PMID: 29566488]
HeLa	IC₅₀	>5 μM Compound: 6i	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay	[PMID: 29566488]
HFL1	IC₅₀	18.2 μM Compound: 6i	Cytotoxicity against human HFL1 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay Cytotoxicity against human HFL1 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay	[PMID: 29566488]
Hs-578T	IC₅₀	1 μM Compound: 6i	Antiproliferative activity against human Hs-578T cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay Antiproliferative activity against human Hs-578T cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay	[PMID: 29566488]
HT-29	IC₅₀	0.4 μM Compound: 6i	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 120 hrs by cell-titer glo assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 120 hrs by cell-titer glo assay	[PMID: 29566488]
LNCaP	IC₅₀	1.06 μM Compound: 6i	Antiproliferative activity against AR-positive human LNCAP cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay Antiproliferative activity against AR-positive human LNCAP cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay	[PMID: 29566488]
LNCaP C4-2B	IC₅₀	2.62 μM Compound: 6i	Antiproliferative activity against AR-positive human C4-2B cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay Antiproliferative activity against AR-positive human C4-2B cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay	[PMID: 29566488]
MCF7	IC₅₀	1 μM Compound: 6i	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay	[PMID: 29566488]
MV4-11	IC₅₀	0.4 μM Compound: 6i	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 120 hrs by cell-titer glo assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 120 hrs by cell-titer glo assay	[PMID: 29566488]
NCI-H1975	IC₅₀	2.5 μM Compound: 6i	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay	[PMID: 29566488]
PC-3	IC₅₀	>3 μM Compound: 6i	Antiproliferative activity against AR-negative human PC-3 cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay Antiproliferative activity against AR-negative human PC-3 cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay	[PMID: 29566488]
U2OS	IC₅₀	>5 μM Compound: 6i	Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay	[PMID: 29566488]
VCaP	IC₅₀	0.63 μM Compound: 6i	Antiproliferative activity against AR-positive human VCaP cells assessed as reduction in cell viability incubated for 144 hrs by cell-titer glo assay Antiproliferative activity against AR-positive human VCaP cells assessed as reduction in cell viability incubated for 144 hrs by cell-titer glo assay	[PMID: 29566488]

In Vitro

Y06036 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC₅₀: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive prostate cancer cell lines LNCaP, C4-2B, 22Rv1, and VCaP. Treatment of 22Rv1 cells with Y06036 (1, 2, 4, 8, and 16 μM, 48 hours) results in significant down-regulation of both full-length (AR-fl) and AR variants levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

LNCaP, C4-2B, 22Rv1, and VCaP prostate cancer cells
Concentration:

0.001-100 μM
Incubation Time:

96 hours for LNCaP, C4-2B, and 22Rv1; 144 hours for VCaP
Result:

Inhibited LNCaP, C4-2B, 22Rv1, and VCaP cells with IC₅₀s of 1.06, 2.62, 1.50, 0.63 μM, respectively.

Western Blot Analysis^[1]

Cell Line:

22Rv1 cells
Concentration:

1,2,4,8, and 16 μM
Incubation Time:

48 hours
Result:

Resulted in significant down-regulation of both AR-fl and AR variants levels

In Vivo

Y06036 (50 mg/kg, i.p. injection, 5 times per week, 25 days) demonstrates therapeutic effects in a C4-2B CRPC xenograft tumor model in mice. Y06036 is well tolerated in the treated mice, based on the weight of the animal body and their general behavior^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Four-week-old male mice (strain: C.B-17/IcrHsd-Prkdc^scid for C4-2B) with C4-2B mouse xenograft model^[1]
Dosage:

50 mg/kg, 100 μL
Administration:

Intraperitoneal (i.p.) injection, 5 times per week, 25 days
Result:

Exhibited strong antitumor activities during the 25-day treatment period, with a tumor growth inhibition (TGI) of 70%.

Chemical Information

CAS No. 1832671-96-1
Appearance Solid
Molecular Weight 427.27
Formula C₁₆H₁₅BrN₂O₅S
Color Light yellow to yellow
SMILES

BrC1=CC(S(=O)(NC2=C(OC)C=C(ON=C3C)C3=C2)=O)=C(OC)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

ACS Nano

Nanopore Discrimination of Protein-Small-Molecule Drug Complexes at Near-Atomic Resolution. [Abstract]

2026 May 12;20(18):13624-13635. PMID: 42046448

Solvent & Solubility

In Vitro:

DMSO : 130 mg/mL (304.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3404 mL

11.7022 mL

23.4044 mL

5 mM

0.4681 mL

2.3404 mL

4.6809 mL

10 mM

0.2340 mL

1.1702 mL

2.3404 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (5.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.17 mg/mL (5.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang M, et al. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). J Med Chem. 2018 Apr 12;61(7):3037-3058. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3404 mL	11.7022 mL	23.4044 mL	58.5110 mL
	5 mM	0.4681 mL	2.3404 mL	4.6809 mL	11.7022 mL
	10 mM	0.2340 mL	1.1702 mL	2.3404 mL	5.8511 mL
	15 mM	0.1560 mL	0.7801 mL	1.5603 mL	3.9007 mL
	20 mM	0.1170 mL	0.5851 mL	1.1702 mL	2.9256 mL
	25 mM	0.0936 mL	0.4681 mL	0.9362 mL	2.3404 mL
	30 mM	0.0780 mL	0.3901 mL	0.7801 mL	1.9504 mL
	40 mM	0.0585 mL	0.2926 mL	0.5851 mL	1.4628 mL
	50 mM	0.0468 mL	0.2340 mL	0.4681 mL	1.1702 mL
	60 mM	0.0390 mL	0.1950 mL	0.3901 mL	0.9752 mL
	80 mM	0.0293 mL	0.1463 mL	0.2926 mL	0.7314 mL
	100 mM	0.0234 mL	0.1170 mL	0.2340 mL	0.5851 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Y06036

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Y06036

All Epigenetic Reader Domain Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Y06036

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Y06036

All Epigenetic Reader Domain Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Y06036 Related Classifications

Cat. No.: HY-111502